Consensus $297.47M. The company said, “Evolysse injectable hyaluronic acid gels contributed approximately 8% of total revenue for the full-year 2025.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M
- Evolus (EOLS): Maintaining Hold Amid Softer Aesthetic Injectables Demand and Macro Headwinds
- Evolus price target lowered to $19 from $20 at Mizuho
- Evolus’s Strategic Growth and Market Resilience Drive Buy Rating
- Evolus, Inc. Earnings Call Highlights Growth and Resilience